H S McCarthy1, S Roberts. 1. Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust and ISTM, Keele University, Oswestry, Shropshire SY10 7AG, UK. Electronic address: Helen.mccarthy@rjah.nhs.uk.
Abstract
OBJECTIVE: In this study, we compare the clinical and histological outcome between periosteum and Chondrogide(®) during autologous chondrocyte implantation (ACI). METHOD: This study consisted of 88 patients having received ACI in the knee; 33 treated with Chondrogide(®) (ACI-C) and 55 with periosteum (ACI-P). Post-operative biopsies were taken at a mean of 16.6 ± 8 months (range 7-37 months) and 19 ± 18.4 months (range 4-114) for ACI-C and ACI-P respectively. Histological assessment was performed using the ICRS II and OsScore scoring systems. The immunolocalisation of elastin and collagen types I and II was analysed using specific antibodies. Lysholm scores, a measure of knee function, were obtained pre- and post-operatively at the time of biopsy and annually thereafter. RESULTS: Compared with ACI-P, the repair tissue formed from patients treated with ACI-C demonstrated a significantly higher score for cellular morphology (ICRS II score), significantly better surface morphology from medial femoral condyle treated defects (ICRS II score) and a significantly higher proportion of hyaline cartilage formation (OsScore). Elastin fibres were present in both ACI-C and ACI-P samples, although their presence was very variable in quantity, distribution, orientation, thickness and length. Patients treated with ACI-C demonstrated significantly more collagen type II immunolocalisation compared with ACI-P. Both groups exhibited a significant increase in Lysholm score post-ACI. CONCLUSIONS: This study demonstrates a significantly better quality of repair tissue formed with ACI-C compared with ACI-P. Hence Chondrogide(®) is perhaps a better alternative to periosteum during ACI.
OBJECTIVE: In this study, we compare the clinical and histological outcome between periosteum and Chondrogide(®) during autologous chondrocyte implantation (ACI). METHOD: This study consisted of 88 patients having received ACI in the knee; 33 treated with Chondrogide(®) (ACI-C) and 55 with periosteum (ACI-P). Post-operative biopsies were taken at a mean of 16.6 ± 8 months (range 7-37 months) and 19 ± 18.4 months (range 4-114) for ACI-C and ACI-P respectively. Histological assessment was performed using the ICRS II and OsScore scoring systems. The immunolocalisation of elastin and collagen types I and II was analysed using specific antibodies. Lysholm scores, a measure of knee function, were obtained pre- and post-operatively at the time of biopsy and annually thereafter. RESULTS: Compared with ACI-P, the repair tissue formed from patients treated with ACI-C demonstrated a significantly higher score for cellular morphology (ICRS II score), significantly better surface morphology from medial femoral condyle treated defects (ICRS II score) and a significantly higher proportion of hyaline cartilage formation (OsScore). Elastin fibres were present in both ACI-C and ACI-P samples, although their presence was very variable in quantity, distribution, orientation, thickness and length. Patients treated with ACI-C demonstrated significantly more collagen type II immunolocalisation compared with ACI-P. Both groups exhibited a significant increase in Lysholm score post-ACI. CONCLUSIONS: This study demonstrates a significantly better quality of repair tissue formed with ACI-C compared with ACI-P. Hence Chondrogide(®) is perhaps a better alternative to periosteum during ACI.
Authors: James D Wylie; Melissa K Hartley; Ashley L Kapron; Stephen K Aoki; Travis G Maak Journal: Clin Orthop Relat Res Date: 2015-05 Impact factor: 4.176
Authors: Shannon R Moore; Céline Heu; Nicole Y C Yu; Renee M Whan; Ulf R Knothe; Stefan Milz; Melissa L Knothe Tate Journal: Stem Cells Transl Med Date: 2016-07-27 Impact factor: 6.940
Authors: Philipp Niemeyer; Gian Salzmann; Matthias Feucht; Jan Pestka; Stella Porichis; Peter Ogon; Norbert Südkamp; Hagen Schmal Journal: Int Orthop Date: 2014-05-17 Impact factor: 3.075